Analysis News
In-depth stock market analysis, technical indicators, and investment commentary. Expert insights on market trends, valuations, and trading strategies.
Nvidia's Dividend Hike: A $6B Gesture, But Buybacks Steal the Show
Nvidia's dividend increase to $0.25 per share will cost $6B quarterly, but buybacks remain the primary capital return tool, with $19.7B repurchased in Q2.
Apple's $120B Slide Ahead of Event Signals Pricing Anxiety
Apple shares fell 2.51%, erasing $120 billion in value days before its September 9 event. Investors now focus on pricing and demand, not just product rumors.
Boeing's F-15EX Milestone: $131B Ceiling vs. Tiny Funded Amount
Boeing moves first F-15EX to Kadena, but the $131B contract ceiling is not backlog; only $343,740 is funded. Stock closes at $212.25, up 0.81%.
Angels' $4B Deal Puts Braves' Valuation in Perspective
A reported $4 billion price for the Angels aligns closely with Atlanta Braves Holdings' enterprise value, but the comparison is less bullish once debt and non-baseball assets are considered.
Cemig's Sá Carvalho Renewal: A Small Step in a Big Concession Puzzle
Cemig's Sá Carvalho renewal covers just 4.4% of its concession exposure, leaving the fate of two larger plants unresolved.
Intel's $21B Surge Sparks Trillion-Dollar Valuation Debate
Intel's stock surged 4.5% on Friday, adding $21B in market cap. Analysts disagree wildly on its value, from $92 to $200 per share, putting a trillion-dollar market cap in question.
Fubo's Disney-Linked Valuation: What Investors Need to Know
FuboTV (FUBO) shares gained 9% last week, but the real story is Disney's 70% economic stake, which changes the valuation math. Fully converted equity is worth $1.23 billion.
AbbVie Completes $10.9B Apogee Buyout, Earnings Lift Delayed to 2032
AbbVie finalizes its $10.9B Apogee Therapeutics deal, with earnings accretion not expected until 2032. The acquisition tests investor patience as immunology sales fuel the wait.
AbbVie Completes $10.9B Apogee Buyout, Accretion Delayed to 2032
AbbVie closes its $10.9B Apogee acquisition, projecting EPS dilution until 2032, while strong Skyrizi and Rinvoq growth funds the long-term bet.
POET Technologies Stock Surges on Shenzhen Showcase, But Revenue Questions Loom
POET Technologies shares rose 8% on its Shenzhen showcase announcement, adding $102M in market value, yet Q2 revenue was just $569,925. The market weighs the company's order book against its modest sales.
SK hynix ADS Premium Hits 46%, Signaling $405B Valuation Gap
SK hynix ADS jumped 8.1% to $177, trading at a 46% premium to Seoul shares. The gap implies a $405B valuation difference, with Solidigm review and buyback in focus.
Intellia's $400M Credit Deal: Modest Initial Draw, Dilution Risk Lingers
Intellia's $400M credit facility starts with just $75M, leaving future tranches conditional. The stock barely moved, as dilution risk persists with an ATM program still active.